A prospective study of oral 5-aminolevulinic acid to prevent adverse events in patients with localized prostate cancer undergoing low-dose-rate brachytherapy: Protocol of the AMBER study.

Discussion: The goal of this trial is to determine the potential benefit of ALA-SFC in patients who undergo LDR-BT. To the best of our knowledge, this is the first study investigating the potential clinical benefit of oral ALA-SFC after radiotherapy. More evidence from a further randomized controlled trial is needed to change the standard of care and lead to better post-radiotherapy management. Trial registration: This clinical trial was prospectively registered with the Japan Registry of Clinical Trials on 5 December 2019. The reference number is jRCTs051190077, nara0013 (Certified Review Board of Nara Medical University). PMID: 32637724 [PubMed]

https://www.ncbi.nlm.nih.gov/pubmed/32637724?dopt=Abstract

Source: Clinical Prostate Cancer - July 10, 2020 Category: Cancer & Oncology Authors: Miyake M, Tanaka N, Asakawa I, Yamaki K, Inoue T, Suzuki S, Hori S, Nakai Y, Anai S, Torimoto K, Toritsuka M, Nakagawa H, Tsukamoto S, Fujii T, Ohbayashi C, Hasegawa M, Kasahara M, Fujimoto K Tags: Contemp Clin Trials Commun Source Type: research